Eli Lilly sees 2026 profit above estimates as demand for weight‑loss drugs soars

Why Eli Lilly Stock Soared Today

Key PointsSales of Lilly's GLP-1 drugs are surging.Management issued a bullish profit forecast. 10 stocks we like better than Eli Lilly › Shares of Eli Lilly (NYSE: LLY) climbed over 10% on Wednesday after the medicine maker delivered a blockbuster earnings report. Image source: Getty Images.Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See…

Lilly soars again as fast-selling weight loss drugs top Wall Street projections

Despite some angst over pricing pressure for GLP-1 drugs, Lilly’s bullish projections surpassed consensus estimates, while combined 2025 sales of Zepbound and Mounjaro eclipsed $36 billion.

Eli Lilly And Co. Profit Advances In Q4

Eli Lilly And Co. (LLY) revealed earnings for its fourth quarter that Increases, from last year The company's earnings totaled $6.636 billion, or $7.39 per share.

Lilly Sees Surging Sales in Break From Weight Loss Rival Novo

Eli Lilly & Co. provided an upbeat sales forecast for the year Wednesday as strong demand for its weight loss drug cemented its position at the top of the obesity market.

Eli Lilly sees 2026 profit above estimates as demand for weight‑loss drugs soars

Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, betting on surging demand for its obesity drugs as the world's most valuable drugmaker prepares to launch its oral weight-loss pill later this year.

Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.